Summary & Overview
HCPCS J0740: Injection, cidofovir, 375 mg
HCPCS Level II code J0740 identifies a 375 mg injection of cidofovir, an antiviral agent used in treatment of severe viral infections requiring parenteral therapy. Nationally, accurate coding for high-cost injectable antivirals matters for clinical documentation, billing integrity, and payer coverage determinations. Reimbursement and coverage policy for such agents influence hospital and outpatient infusion workflows and patient access to treatment.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what the code denotes, typical sites of service, commonly used modifiers, and the payer landscape reflected in coverage and billing practice. The publication summarizes benchmark elements relevant to billing and claims processing, highlights policy considerations affecting access and reimbursement, and provides clinical context for when parenteral cidofovir may be administered.
This resource is intended for billing professionals, revenue cycle leaders, and clinical administrators seeking concise guidance on coding, payer interactions, and the operational implications of administering cidofovir in hospital and outpatient infusion settings.
Billing Code Overview
HCPCS Level II code J0740 describes an injection of cidofovir, 375 mg. This billing code represents a single-dose parenteral administration of cidofovir, an antiviral medication used in certain serious viral infections.
-
Service type: Injectable antiviral medication administration
-
Typical site of service: Hospital inpatient, hospital outpatient, or other outpatient infusion setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a confirmed or suspected DNA viral infection resistant to first-line antiviral therapies or with contraindications to standard agents (for example cytomegalovirus [CMV] infection in an immunocompromised patient). The patient presents to an infusion center or hospital outpatient infusion clinic for administration of cidofovir (J0740) as an intravenous antiviral agent. Prior to the infusion, the clinical team confirms indications, reviews baseline renal function and electrolytes, and documents informed consent. Prophylactic measures (prehydration with normal saline and probenecid administration per institutional protocol) are arranged to reduce nephrotoxicity risk. The pharmacy compounds the 375 mg cidofovir dose per order and hands off to nursing. The nurse verifies patient identity, allergy status, and venous access, then administers cidofovir via slow IV infusion over the recommended time with continuous monitoring for infusion reactions and vitals at regular intervals. Post-infusion monitoring includes renal function checks and documentation of any adverse events. Billing for the drug is submitted using HCPCS Level II code J0740 with applicable modifiers to reflect payer-specific circumstances or services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 |